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CHAPTER 3. RESULTS 








































































































































































































































































Model		 DriverNet1	 COSMIC	 DriverNet2	 remMap	 remMap.CNAmet	 CV300	
Primary	
metric	
0.273	 0.268	 0.268	 0.265	 0.266	 0.199	
Tie	
metric	
0.278	 0.272	 0.272	 0.270	 0.270	 0.201	
	
Table	2.B	Primary	and	Tie	Metrics	of	Each	Model	in	Challenge	B	
Model	 COSMIC	(B)	 DriverNet2	(B)	 DriverNet1	(B)	 CNAmet	
Primary	
metric	
0.266	 0.261	 0.272	 0.240	





































































































































































































4.3 Conclusions  
Research	in	data	integration	and	in	drug	synergy	analysis	has	mostly	remained	
isolated.	Our	study	suggests	that	the	application	of	data	integration	approach	may	
improve	our	understanding	of	targeted	drug	synergies.	The	emergence	of	data	
integration	methods	will	facilitate	the	process	of	variable	selection	for	models	to	
predict	drug	synergies.	Although	the	need	for	a	systematic	integrative	analysis	
method	has	not	been	fully	addressed	yet,	there	are	various	approaches	that	can	be	
	 34	
implemented	in	future	studies.	The	major	challenge	of	incorporating	data	
integration	analysis	into	drug	synergies	study	is	to	combine	different	types	of	omics	
datasets	and	drug	information.	As	more	data	are	generated	across	multiple	data	
types,	novel	integration	methodologies	of	future	will	further	our	understanding	of	
important	biological	processes	of	gene-gene	and	drug-gene	interactions.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 35	
BIBLIOGRAPHY 
	
1. Jia	J,	Zhu	F,	Ma	X,	et	al.	Mechanisms	of	drug	combinations:	interaction	and	
network	perspectives[J].	Nature	reviews	Drug	discovery,	2009,	8(2):	111-
128.	
2. J.	Foucquier,	M.	Guedj.	Analysis	of	drug	combinations:	current	
methodological	landscape,	Pharma	Res	Per,	3(3),	2015,	e00149,	
doi:	10.1002/prp2.149	
3. Lee,	E.	J.,	Whang,	J.	H.,	Jeon,	N.	K.	&	Kim,	J.	The	epidermal	growth	factor	
receptor	tyrosine	kinase	inhibitor	ZD1839	(Iressa)	suppresses	proliferation	
and	invasion	of	human	oral	squamous	carcinoma	cells	via	p53	independent	
and	MMP,	uPAR	dependent	mechanism.	Ann.	NY	Acad.	Sci.	1095,	113–128 
(2007).	
4. Fanucchi,	M.	&	Khuri,	F.	R.	Taxanes	in	the	treatment	of	non-small	cell	lung	
cancer.Treat.	Respir.	Med.	5,	181–191	(2006).	
5. Takabatake,	D.	et	al.	Tumor	inhibitory	effect	of	gefitinib	(ZD1839,	Iressa)	and	
taxane	combination	therapy	in	EGFR-overexpressing	breast	cancer	cell	lines	
(MCF7/ADR,	MDA-MB-231).	Int.	J.	Cancer	120,	181–188	(2007).	
6. Lehár	J,	Krueger	A	S,	Avery	W,	et	al.	Synergistic	drug	combinations	tend	to	
improve	therapeutically	relevant	selectivity[J].	Nature	biotechnology,	2009,	
27(7):	659-666.	
7. Barretina	J,	Caponigro	G,	Stransky	N,	Venkatesan	K,	Margolin	AA,	et	al.	(2012)	
The	Cancer	Cell	Line	Encyclopedia	enables	predictive	modelling	of	anticancer	
drug	sensitivity.	Nature	483:	603–607.	doi:	10.1038/nature11003.	
pmid:22460905	
8. Garnett	MJ,	Edelman	EJ,	Heidorn	SJ,	Greenman	CD,	Dastur	A,	et	al.	(2012)	
Systematic	identification	of	genomic	markers	of	drug	sensitivity	in	cancer	
cells.	Nature	483:	570–575.	doi:	10.1038/nature11005.	pmid:22460902	
	 36	
9. Costello	J	C,	Heiser	L	M,	Georgii	E,	et	al.	A	community	effort	to	assess	and	
improve	drug	sensitivity	prediction	algorithms[J].	Nature	biotechnology,	
2014,	32(12):	1202-1212.	
10. Lappalainen	T,	Sammeth	M,	Friedländer	M	R,	et	al.	Transcriptome	and	
genome	sequencing	uncovers	functional	variation	in	humans[J].	Nature,	
2013,	501(7468):	506-511.	
11. Cheng	L,	Wang	P,	Yang	S,	Yang	Y,	Zhang	Q,	Zhang	W,	Xiao	H,	Gao	H,	Zhang	Q	
(2012)	Identification	of	genes	with	a	correlation	between	copy	number	and	
expression	in	gastric	cancer.	BMC	Med	Genomics	5:14	
12. Bussey	K	J,	Chin	K,	Lababidi	S,	et	al.	Integrating	data	on	DNA	copy	number	
with	gene	expression	levels	and	drug	sensitivities	in	the	NCI-60	cell	line	
panel[J].	Molecular	cancer	therapeutics,	2006,	5(4):	853-867.	
13. “The	AstraZeneca-Sanger	Drug	Combination	Prediction	Challenge	
(Syn4231880)”	2015–2016	
14. Lawrence,	Michael	S,	Petar	Stojanov,	Paz	Polak,	Gregory	V	Kryukov,	Kristian	
Cibulskis,	Andrey	Sivachenko,	Scott	L	Carter,	et	al.	2013.	“Mutational	
Heterogeneity	in	Cancer	and	the	Search	for	New	Cancer-Associated	
Genes.”	Nature	499	(7457).	Nature	Publishing	Group:	214–18.	
15. Kasprzyk,	Arek.	2011.	“BioMart:	Driving	a	Paradigm	Change	in	Biological	
Data	Management.”	Database	2011.	Oxford	University	Press:	bar049.	
16. Bashashati,	Ali,	Gholamreza	Haffari,	Jiarui	Ding,	Gavin	Ha,	Kenneth	Lui,	Jamie	
Rosner,	David	G	Huntsman,	Carlos	Caldas,	Samuel	A	Aparicio,	and	Sohrab	P	
Shah.	2012.	“DriverNet:	Uncovering	the	Impact	of	Somatic	Driver	Mutations	
on	Transcriptional	Networks	in	Cancer.”	Genome	Biol13	(12).	Springer	
Science	Business	Media:	R124.	doi:10.1186/gb-2012-13-12-r124	
17. http://www.reactome.org/	
18. Peng	J,	Zhu	J,	Bergamaschi	A,	et	al.	Regularized	multivariate	regression	for	
identifying	master	predictors	with	application	to	integrative	genomics	study	
of	breast	cancer[J].	The	annals	of	applied	statistics,	2010,	4(1):	53.	
19. Friedman	J,	Hastie	T,	Tibshirani	R.	A	note	on	the	group	lasso	and	a	sparse	
group	lasso[J].	arXiv	preprint	arXiv:1001.0736,	2010.	
	 37	
20. Louhimo	R,	Hautaniemi	S.	CNAmet:	an	R	package	for	integrating	copy	
number,	methylation	and	expression	data[J].	Bioinformatics,	2011,	27(6):	
887-888.	
21. Forbes,	Simon	A,	David	Beare,	Prasad	Gunasekaran,	Kenric	Leung,	Nidhi	
Bindal,	Harry	Boutselakis,	Minjie	Ding,	et	al.	2015.	“COSMIC:	Exploring	the	
World’s	Knowledge	of	Somatic	Mutations	in	Human	Cancer.”	Nucleic	Acids	
Research	43	(D1).	Oxford	Univ	Press:	D805–D811.	
22. Liaw	A,	Wiener	M.	Classification	and	regression	by	randomForest[J].	R	news,	
2002,	2(3):	18-22.	
23. Zhang	L,	Liu	Y,	Song	F,	et	al.	Functional	SNP	in	the	microRNA-367	binding	site	
in	the	3′	UTR	of	the	calcium	channel	ryanodine	receptor	gene	3	(RYR3)	
affects	breast	cancer	risk	and	calcification[J].	Proceedings	of	the	National	
Academy	of	Sciences,	2011,	108(33):	13653-13658.	
24. Kallioniemi	O	P,	Kallioniemi	A,	Kurisu	W,	et	al.	ERBB2	amplification	in	breast	
cancer	analyzed	by	fluorescence	in	situ	hybridization[J].	Proceedings	of	the	
National	Academy	of	Sciences,	1992,	89(12):	5321-5325.	
25. Shiu	KK,	Natrajan	R,	Geyer	FC,	Ashworth	A,	Reis-Filho	JS.	DNA	amplifications	
in	breast	cancer:	genotypic-phenotypic	correlations.	Future	
Oncol.	2010;14:967–984.	doi:	10.2217/fon.10.56.	
26. Wu	G,	Feng	X,	Stein	L.	Research	a	human	functional	protein	interaction	
network	and	its	application	to	cancer	data	analysis[J].	Genome	Biol,	2010,	11:	
R53.	
27. Scoring	metrics,	
https://www.synapse.org/#!Synapse:syn4231880/wiki/235660	
28. Chen	D,	Liu	X,	Yang	Y,	et	al.	Systematic	synergy	modeling:	understanding	
drug	synergy	from	a	systems	biology	perspective[J].	BMC	systems	biology,	
2015,	9(1):	56.	
29. Sun	Y,	et	al.	Combining	genomic	and	network	characteristics	for	extended	
capability	in	predicting	synergistic	drugs	for	cancer.	Nat	
Commun.	2015;6:8481.	
	 38	
30. Yang,	J.,	Tang,	H.,	Li,	Y.,	Zhong,	R.,	Wang,	T.,	Wong,	S.,	Xiao,	G.	and	Xie,	Y.	
(2015),	DIGRE:	Drug-Induced	Genomic	Residual	Effect	Model	for	Successful	
Prediction	of	Multidrug	Effects.	CPT:	Pharmacometrics	&	Systems	
Pharmacology,	4:	91–97.	doi:	10.1002/psp4.1.	
31. Chen,	Di	and	Zhang,	Huamin	and	Lu,	Peng	and	Liu,	Xianli	and	Cao,	Hongxin.	
Synergy	evaluation	by	a	pathway-pathway	interaction	network:	a	new	way	to	
predict	drug	combination.	Molecular	BioSystems,	2016,	2:	614—623.		
32. Zhao	X	M,	Iskar	M,	Zeller	G,	et	al.	Prediction	of	drug	combinations	by	
integrating	molecular	and	pharmacological	data[J].	PLoS	Comput	Biol,	2011,	
7(12):	e1002323.	
33. Louie	B,	Mork	P,	Martin-Sanchez	F,	et	al.	Data	integration	and	genomic	
medicine[J].	Journal	of	biomedical	informatics,	2007,	40(1):	5-16.	
34. Ritchie	M	D,	Holzinger	E	R,	Li	R,	et	al.	Methods	of	integrating	data	to	uncover	
genotype-phenotype	interactions[J].	Nature	Reviews	Genetics,	2015,	16(2):	
85-97.	
35. Kristensen	V	N,	Lingjærde	O	C,	Russnes	H	G,	et	al.	Principles	and	methods	of	
integrative	genomic	analyses	in	cancer[J].	Nature	Reviews	Cancer,	2014,	
14(5):	299-313.	
36. Breiman	L.	Random	forests[J].	Machine	learning,	2001,	45(1):	5-32.	
37. Kim	D,	Joung	J	G,	Sohn	K	A,	et	al.	Knowledge	boosting:	a	graph-based	
integration	approach	with	multi-omics	data	and	genomic	knowledge	for	
cancer	clinical	outcome	prediction[J].	Journal	of	the	American	Medical	
Informatics	Association,	2014:	amiajnl-2013-002481.	
38. Gevaert	O,	De	Moor	B.	Prediction	of	cancer	outcome	using	DNA	microarray	
technology:	past,	present	and	future[J].	Expert	opinion	on	medical	
diagnostics,	2009,	3(2):	157-165.	
39. Dorel	M,	Barillot	E,	Zinovyev	A,	et	al.	Network-based	approaches	for	drug	
response	prediction	and	targeted	therapy	development	in	cancer[J].	
Biochemical	and	biophysical	research	communications,	2015,	464(2):	386-
391.	
	 39	
40. Vera-Licona	P,	Bonnet	E,	Barillot	E,	et	al.	OCSANA:	optimal	combinations	of	
interventions	from	network	analysis[J].	Bioinformatics,	2013,	29(12):	1571-
1573.	
41. Azmi	A	S,	Wang	Z,	Philip	P	A,	et	al.	Proof	of	concept:	network	and	systems	
biology	approaches	aid	in	the	discovery	of	potent	anticancer	drug	
combinations[J].	Molecular	cancer	therapeutics,	2010,	9(12):	3137-3144.	
42. Pal	R,	Berlow	N.	A	kinase	inhibition	map	approach	for	tumor	sensitivity	
prediction	and	combination	therapy	design	for	targeted	drugs[C]//Pac	Symp	
Biocomput.	2012,	351:	62.	
43. Wan	Q,	Pal	R.	An	ensemble	based	top	performing	approach	for	NCI-DREAM	
drug	sensitivity	prediction	challenge[J].	PloS	one,	2014,	9(6):	e101183.	
